Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2023 | Buy → Neutral | Mizuho | |
| 1/6/2022 | $28.00 → $6.00 | Buy | Mizuho |
| 1/5/2022 | $22.00 → $6.00 | Overweight | Barclays |
| 1/5/2022 | $7.00 → $3.00 | Equal-Weight | Morgan Stanley |
| 1/5/2022 | Buy → Neutral | BTIG | |
| 1/5/2022 | $28.00 → $8.00 | Buy | Needham |
| 11/19/2021 | $24.00 → $7.00 | Overweight → Equal-Weight | Morgan Stanley |
| 10/12/2021 | $27.00 → $25.00 | Overweight | Morgan Stanley |
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str
Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on promising initial Phase 1A data; confirmatory Phase 1A data expected mid-2024 and topline Phase 1B data expected in 2025 Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced the initiation of enrollment in the Phase 1B study for TX45, an investigational long-acting relaxin-Fc fu
Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, co-founded by Timothy A. Springer and Andrew C. Kruse of Harvard Medical School, today announced that Alise Reicin, MD, President and Chief Executive Officer, will be participating in two investor conferences in March: TD Cowen 44th Annual Health Care Conference being held in Boston on March 4 – 6 Leerink Partners Global Biopharma Conference being held in Miami on March 11 – 13 The Tectonic management team will host one-on-one meetings during both conferences. Interested investors should contact their TD Cowen and/or Leerink rep
Mizuho downgraded AVROBIO from Buy to Neutral
Mizuho reiterated coverage of Avrobio with a rating of Buy and set a new price target of $6.00 from $28.00 previously
Barclays reiterated coverage of Avrobio with a rating of Overweight and set a new price target of $6.00 from $22.00 previously
Tectonic Therapeutic, Inc. ("Tectonic"), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic. "Dan is an experienced public-company CFO who will add significant financial expertise to our team," said Alise Reicin, MD, President and Chief Executive Officer of Tectonic. "With his extensive background in the healthcare and biopharmaceutical industries, Dan is an important addition to the Tectonic team, and we are thrilled to welcome him as Chief Financial Officer." Dan brings with him a wealth of knowledge in corporate finance, business str
Combined company to be Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Tectonic's novel GPCR-targeted therapeutic proteins $130.7 million in private financing commitments with new and existing leading life sciences investors in connection with merger Combined company expected to have approximately $165 million in cash and cash equivalents at close to provide cash runway into mid-2027 Funding is expected to advance lead asset TX45, a potential best-in-class Fc-relaxin fusion protein, through multiple clinical data catalysts Tectonic's first two programs address indications with high unmet need and no approved therapies Companies to host joint webcast to
On track to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment Plan to provide clinical and regulatory updates on cystinosis program in conjunction with ASGCT annual meeting in May 2023; plan to initiate late-stage cystinosis clinical trial activities in second half 2023, subject to regulatory alignment Collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, initiated Announced appointment of current CFO Erik Ostrowski as interim CEO AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a l
SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13G/A - AVROBIO, Inc. (0001681087) (Subject)
Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1+ year post-gene therapy in Phase 1/2 clinical triali for cystinosis; all remain off oral cysteamine to date Interim clinical data update of AVR-RD-02 in Gaucher disease type 1 planned for 2022; third patient dosed in Phase 1/2 clinical trial Regulatory interactions planned in 2022 to inform clinical development and registration strategies for programs in Gaucher disease, cystinosis, Hunter syndrome and Pompe disease Strong balance sheet with cash runway into Q1 2024 AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a li
Sustained engraftment observed across first three patients 1+ year post-gene therapy; all remain off oral cysteamine to date Reduction in number of cystine crystals as measured in skin and intestinal mucosa biopsies observed across first three patients Continued favorable safety profile with no adverse events related to drug product to date Clinical proof-of-concept in adult patients lays groundwork for AVROBIO-sponsored trial planned to begin in 2023 Analyst and investor conference call scheduled for today at 8:00 a.m. ET AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today reported
Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022, at 8:00 a.m. ET Five platform presentations and three posters on the company's clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that updated clinical data from its ongoing, collaborator-sponsoredi Phase 1/2 clinical trial in cystinosis will be presented on Feb. 9, 2022, at the 18th Annual WORLDSymposium™ in San Diego, Calif. Additionally, preclinical data from its Pompe disease and Hunter syndrome programs, as we
4 - AVROBIO, Inc. (0001681087) (Issuer)
8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
8-K/A - AVROBIO, Inc. (0001681087) (Filer)